AbbVie Inc. $ABBV Shares Purchased by Mn Services Vermogensbeheer B.V.

Key Points

• Mn Services Vermogensbeheer increased its AbbVie stake by 1.4% in the third quarter, bringing its holdings to 522,459 shares valued at approximately $136.7 million. Institutional investors and hedge funds collectively own 70.23% of ABBV.
• AbbVie received two FDA Breakthrough Therapy Designations for Temab-A, while Phase 3 data showed epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
• Analysts maintain a favorable outlook, with an average price target of $276.64 and recent target increases from JPMorgan and Cantor Fitzgerald. However, AbbVie’s elevated dividend payout ratio of roughly 195% raises concerns about long-term dividend coverage.

Mn Services Vermogensbeheer B.V. grew its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 1.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 522,459 shares of the company's stock after purchasing an additional 7,100 shares during the period. AbbVie comprises about 1.0% of Mn Services Vermogensbeheer B.V.'s investment portfolio, making the stock its 20th biggest position. Mn Services Vermogensbeheer B.V.'s holdings in AbbVie were worth $136,670,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in ABBV. State Street Corp grew its holdings in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company's stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock worth $3,590,323,000 after buying an additional 106,091 shares in the last quarter. Legal & General Group Plc bought a new stake in AbbVie in the 2nd quarter valued at $2,905,952,000. Deutsche Bank AG raised its stake in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock valued at $2,710,905,000 after buying an additional 1,241,587 shares in the last quarter. Finally, Amundi lifted its holdings in shares of AbbVie by 2.4% during the 1st quarter. Amundi now owns 10,698,095 shares of the company's stock worth $2,326,728,000 after acquiring an additional 247,689 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations for Temab-A: The FDA granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, while highlighting the potential of AbbVie’s antibody-drug conjugate portfolio. They do not, however, represent an approval or guarantee of commercial success. AbbVie Temab-A FDA Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 lymphoma data: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly/Epkinly and adds another meaningful pipeline catalyst. AbbVie and Genmab Epcoritamab Phase 3 Results
• Positive Sentiment: Higher analyst price targets: JPMorgan raised its AbbVie target to $300 from $285 and maintained an Overweight rating. Cantor Fitzgerald also raised its target, to $290 from $285, and reiterated Overweight. The revisions indicate analysts see additional upside based on AbbVie’s pipeline and growth outlook.
• Negative Sentiment: Dividend sustainability concerns: A report highlighted AbbVie’s roughly 190% payout ratio, meaning reported earnings are below the dividend distributed. While noncash charges and other accounting factors can distort this measure, the elevated ratio raises questions about long-term dividend coverage and could weigh on income-focused investors. AbbVie Dividend Payout Concerns

AbbVie Price Performance

ABBV stock opened at $272.20 on Friday. The company has a 50 day moving average price of $258.56 and a 200 day moving average price of $236.35. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $274.94. The stock has a market capitalization of $480.92 billion, a PE ratio of 76.89, a price-to-earnings-growth ratio of 1.23 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts expect that AbbVie Inc. will post 14.01 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald lifted their price objective on AbbVie from $285.00 to $290.00 and gave the company an "overweight" rating in a report on Thursday. Leerink Partners increased their price objective on AbbVie from $245.00 to $279.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. boosted their target price on shares of AbbVie from $285.00 to $300.00 and gave the company an "overweight" rating in a research note on Thursday. Sanford C. Bernstein reissued a "market perform" rating and set a $225.00 price target (up from $203.00) on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Guggenheim raised their price objective on shares of AbbVie from $261.00 to $288.00 and gave the stock a "buy" rating in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $276.64.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.